Medicure (CVE:MPH) Trading Up 10.7% – Time to Buy?

Medicure Inc. (CVE:MPH) shares were up 10.7% on Monday . The company traded as high as C$1.35 and last traded at C$1.35. Approximately 2,730 shares changed hands during trading, an increase of 25% from the average daily volume of 2,192 shares. The stock had previously closed at C$1.22.

Medicure Stock Performance

The firm has a market capitalization of C$14.09 million, a PE ratio of -4.09 and a beta of 0.66. The company has a current ratio of 1.44, a quick ratio of 1.29 and a debt-to-equity ratio of 5.78. The business’s 50 day simple moving average is C$1.10 and its two-hundred day simple moving average is C$1.15.

About Medicure

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.